List drug and therapy programmes
list_assetsRead-onlyIdempotent
Drug and therapy programmes in development (assets), furthest stage first: each with its developers and partners, code names, modality, targets, mechanism, indications with the stage of each, hallmarks of aging and lifespan evidence. Narrow by target (a gene symbol such as GLP1R, or a process), mechanism words, modality, hallmark, indication, stage, the developer's country, an organisation or a name. Read one in full with get_asset; count them with count_pipeline. An account whose plan includes drug and therapy programmes reads every record in full; any other caller reads the outline AgingResearch.News shows on its asset pages.
Input Schema
TableJSON Schema
| Name | Required | Description | Default |
|---|---|---|---|
| q | No | Letters and digits in any of the asset's names or code names (`UBX1325` matches UBX-1325). | |
| limit | No | Results per page, 1 to 25. | |
| stage | No | Stage: with `indication`, the stage for that indication; otherwise the asset's furthest stage. | |
| cursor | No | Opaque cursor from `pagination.next_cursor` of the previous page. Keep the other parameters the same. | |
| target | No | A target: a gene symbol or key (`GLP1R`, `bcl2l1`) or a process key (`mtor`, `cellular-senescence`). | |
| country | No | The developer's country, ISO 3166 alpha-2 (`US`, `GB`, `CH`). | |
| hallmark | No | A hallmark of aging the asset acts on. | |
| modality | No | The kind of therapy (see `modality`). | |
| mechanism | No | Words that must all appear in the asset's mechanism line (case-insensitive). | |
| indication | No | A disease, by name or entity key (`idiopathic pulmonary fibrosis`, `alzheimer-disease`). | |
| organisation | No | An organisation key: the assets it develops, partners on or licensed out. |